secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2023-09-07T23:59:59+00:00
Accession:  0000950170-23-047036
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista reports Q1 FY2024 net loss $25.3M; KONFIDENT phase 3 enrollment achieved
--------------------------------------------------------------------------------

- Net loss $25.3M ($0.74/share) vs $23.0M ($0.94/share) in prior-year quarter.
- Cash, equivalents and marketable securities $123.3M vs $149.4M as of April 30, 2023.
- Phase 3 KONFIDENT trial for sebetralstat hit enrollment target of 114 patients; data readout on track for Q4 2023.
- NDA submission planned for H1 2024; Nicole Sweeny appointed Chief Commercial Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017023047036/0000950170-23-047036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017023047036/kalv-20230907.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-047036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer